Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (364)	1/6/1999 1:03:00 AM
From: scaram(o)uche	Respond to of 1073

Joe: Yeah, I remember the CEGE hype. At that time, I figured that AVGN was in deep trouble. However, there are still use patents to be had, even if someone does hold a broad, enabling claim for AAV. The epo patent to AVGN did issue, and one can probably find others. That means that CEGE would need to scratch the back of a variety of companies that might want to practice the art, even if their protection is as broad as they claim. Patents are always a mess. I think it's a scam among attorneys to guarantee employment ops. I think a good starting point would be to simply get the relevant patent number from CEGE. I know that there was some work at NIH in the mid-eighties, and I also know that the old Applied Immune Sciences was doing vector work with AAV in the late eighties. Maybe CEGE licensed the NIH work? Anyone know the relevant patent number so we can go straight to it? This is just simply an area where I don't know much. But, if you take "covering all gene therapy products that utilize AAV vectors" at face value...... sort of tough to beat. Thanks, Joe. Rick